Hokuyaku Takeyama HoldingsInc Management
Management criteria checks 0/4
Hokuyaku Takeyama HoldingsInc's CEO is Masanobu Manabe, appointed in Jun 2018, has a tenure of 6.5 years. directly owns 0.11% of the company’s shares, worth ¥20.38M. The average tenure of the management team and the board of directors is 1.9 years and 1.9 years respectively.
Key information
Masanobu Manabe
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.9yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
Does Hokuyaku Takeyama Holdings,Inc. (SPSE:3055) Have A Place In Your Dividend Portfolio?
Apr 15
What Kind Of Shareholders Hold The Majority In Hokuyaku Takeyama Holdings,Inc.'s (SPSE:3055) Shares?
Mar 08Will Hokuyaku Takeyama HoldingsInc (SPSE:3055) Multiply In Value Going Forward?
Feb 15Are Hokuyaku Takeyama HoldingsInc's (SPSE:3055) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 28Does Hokuyaku Takeyama Holdings,Inc. (SPSE:3055) Have A Place In Your Dividend Portfolio?
Jan 10
Introducing Hokuyaku Takeyama HoldingsInc (SPSE:3055), A Stock That Climbed 14% In The Last Five Years
Dec 23What Type Of Shareholders Own The Most Number of Hokuyaku Takeyama Holdings,Inc. (SPSE:3055) Shares?
Dec 05CEO
Masanobu Manabe (58 yo)
6.5yrs
Tenure
Mr. Masanobu Manabe had been Vice President and Administrator of Pharmaceutical Business of Hokuyaku Takeyama Holdings Inc., since June 2014 and June 2015 respectively. Mr. Manabe served as a Senior Managi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.5yrs | no data | 0.11% ¥ 20.4m | |
| ICT Business Manager | less than a year | no data | 1.76% ¥ 314.1m | |
| Executive Officer | 1.9yrs | no data | 0.019% ¥ 3.4m | |
| Head of Pharmaceutical Wholesale Business & Director | 10.5yrs | no data | 0.047% ¥ 8.5m | |
| GM of Administration Headquarters & Management Division and Director | 1.9yrs | no data | no data | |
| Pharmacy Business Manager & Director | 1.5yrs | no data | no data | |
| Senior Executive Officer & Chief Director of IT Strategy Headquarters | 5.4yrs | no data | no data | |
| Senior Executive Officer & CEO of the Management Headquarters | 1.5yrs | no data | no data |
1.9yrs
Average Tenure
60yo
Average Age
Experienced Management: 3055's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18.3yrs | no data | 0.11% ¥ 20.4m | |
| ICT Business Manager | 18.3yrs | no data | 1.76% ¥ 314.1m | |
| Head of Pharmaceutical Wholesale Business & Director | less than a year | no data | 0.047% ¥ 8.5m | |
| GM of Administration Headquarters & Management Division and Director | 1.9yrs | no data | no data | |
| Pharmacy Business Manager & Director | less than a year | no data | no data | |
| Chairman of the Board | 18.3yrs | no data | 1.57% ¥ 280.2m | |
| External Auditor | 18.3yrs | no data | 0.057% ¥ 10.2m | |
| Director | less than a year | no data | 0.057% ¥ 10.2m | |
| Director | less than a year | no data | 0.028% ¥ 5.1m | |
| 2.9yrs | no data | no data | ||
| Independent Outside Director | 1.5yrs | no data | no data |
1.9yrs
Average Tenure
63yo
Average Age
Experienced Board: 3055's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 21:49 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hokuyaku Takeyama Holdings,Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|